Yu, Evan Y <br/><br/>
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 2010 
 - 2668-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.25.1330  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Analysis of Variance<br/>Androgen Antagonists--administration & dosage<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Brachytherapy--methods<br/>Castration<br/>Cause of Death<br/>Chemotherapy, Adjuvant<br/>Confidence Intervals<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Flutamide--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Leuprolide--administration & dosage<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Probability<br/>Prospective Studies<br/>Prostate-Specific Antigen--blood<br/>Prostatectomy--methods<br/>Prostatic Neoplasms--mortality<br/>Risk Assessment<br/>Salvage Therapy--methods<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome